US OptionsDetailed Quotes
GH241115C18000
- 3.40
- 0.000.00%
15min DelayClose Oct 25 16:00 ET
0.00High0.00Low
3.40Open3.40Pre Close0 Volume4 Open Interest18.00Strike Price0.00Turnover104.18%IV4.34%PremiumNov 15, 2024Expiry Date2.51Intrinsic Value100Multiplier18DDays to Expiry0.89Extrinsic Value100Contract SizeAmericanOptions Type0.7527Delta0.0656Gamma6.12Leverage Ratio-0.0429Theta0.0061Rho4.61Eff Leverage0.0146Vega
Guardant Health Stock Discussion
Sign in to post a comment
Morning Movers
Gapping up
$BJ's Wholesale Club Holdings (BJ.US)$ Shares rose more than 1.1% after JPMorgan upgraded the wholesaler to neutral from underweight as the company reinvests in its business and benefits from consumers trading down.
$Planet Fitness (PLNT.US)$
Shares increased by 1.15% after Baird maintained its overweight rating and added a "bullish fresh pick" designation through year-end for Planet Fitness. The firm e...
Gapping up
$BJ's Wholesale Club Holdings (BJ.US)$ Shares rose more than 1.1% after JPMorgan upgraded the wholesaler to neutral from underweight as the company reinvests in its business and benefits from consumers trading down.
$Planet Fitness (PLNT.US)$
Shares increased by 1.15% after Baird maintained its overweight rating and added a "bullish fresh pick" designation through year-end for Planet Fitness. The firm e...
39
1
Guardant Health is undervalued, making it a good time to accumulate more holdings. The company's positive future outlook isn't fully reflected in the current share price. Consider financial health before investing.
1
The recent share price drop may indicate unresolved challenges, despite the company's revenue growth. Investors are advised to ensure they are buying a high-quality business, even when the share price is low.
Guardant Health's high P/S ratio is due to strong revenue performance and promising future growth rates, bolstering shareholder confidence. Given the optimism, a significant stock price drop is unlikely soon.
Substantial insider acquisitions point to optimism for the company's prospects. However, the recent sale by the CIO may suggest some insiders think shares are overvalued. Still, high insider ownership implies alignment of management's interests with shareholders.
Wolfe Research Downgrades $Snowflake (SNOW.US)$ to Peer Perform From Outperform
Snowflake (SNOW) has an average rating of outperform and price targets ranging from $105 to $500, according to analysts polled by Capital IQ.
Guggenheim Downgrades $MongoDB (MDB.US)$ to Sell From Neutral, Adjusts Price Target to $210 From $205
MongoDB (MDB) has an average rating of outperform and price targets ranging from $180 to $365, according to analysts po...
Snowflake (SNOW) has an average rating of outperform and price targets ranging from $105 to $500, according to analysts polled by Capital IQ.
Guggenheim Downgrades $MongoDB (MDB.US)$ to Sell From Neutral, Adjusts Price Target to $210 From $205
MongoDB (MDB) has an average rating of outperform and price targets ranging from $180 to $365, according to analysts po...
18
1
Gapping up
$Adobe (ADBE.US)$ +4.6%(The software company reported better-than-expected quarterly earnings and revenue that was in line with analyst forecasts. Adobe also issued upbeat current quarter guidance.)
$Darden Restaurants (DRI.US)$ +1% (The parent of Olive Garden and other restaurant chains reported for its latest quarter, and exceeded analyst forecasts for same-restaurant sales. Darden also raised the lower end of its 2023 ea...
$Adobe (ADBE.US)$ +4.6%(The software company reported better-than-expected quarterly earnings and revenue that was in line with analyst forecasts. Adobe also issued upbeat current quarter guidance.)
$Darden Restaurants (DRI.US)$ +1% (The parent of Olive Garden and other restaurant chains reported for its latest quarter, and exceeded analyst forecasts for same-restaurant sales. Darden also raised the lower end of its 2023 ea...
9
Gainers:
In reaction to earnings/guidance:
• $Karuna Therapeutics (KRTX.US)$ +42.6% (also reports topline results from its Phase3 EMERGENT-2 trial evaluating the efficacy, safety, and tolerability of its lead investigational therapy, KarXT), $monday.com (MNDY.US)$ +15.1%, $W&T Offshore (WTI.US)$ +6.7%, $HF Sinclair (DINO.US)$ +5.3%, $Viatris (VTRS.US)$ +4.3%, $Kosmos Energy (KOS.US)$ + 3.2%, $Holly Energy (HEP.US)$ +3.2%, $Barrick Gold (GOLD.US)$ +2.9%, ...
In reaction to earnings/guidance:
• $Karuna Therapeutics (KRTX.US)$ +42.6% (also reports topline results from its Phase3 EMERGENT-2 trial evaluating the efficacy, safety, and tolerability of its lead investigational therapy, KarXT), $monday.com (MNDY.US)$ +15.1%, $W&T Offshore (WTI.US)$ +6.7%, $HF Sinclair (DINO.US)$ +5.3%, $Viatris (VTRS.US)$ +4.3%, $Kosmos Energy (KOS.US)$ + 3.2%, $Holly Energy (HEP.US)$ +3.2%, $Barrick Gold (GOLD.US)$ +2.9%, ...
16
2
No comment yet
kenjolim : hi